Mainz Biomed Analyst Ratings
Mainz Biomed Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/20/2023 | 309.84% | HC Wainwright & Co. | $9 → $5 | Maintains | Buy |
| 09/26/2023 | 637.7% | Cantor Fitzgerald | → $9 | Reiterates | Overweight → Overweight |
| 09/22/2023 | 637.7% | HC Wainwright & Co. | $7 → $9 | Maintains | Buy |
| 09/14/2023 | 637.7% | Cantor Fitzgerald | → $9 | Reiterates | Overweight → Overweight |
| 08/22/2023 | 637.7% | Cantor Fitzgerald | → $9 | Reiterates | Overweight → Overweight |
| 08/18/2023 | 473.77% | HC Wainwright & Co. | $10 → $7 | Reiterates | Buy → Buy |
| 06/01/2023 | 719.67% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 05/18/2023 | 883.61% | Cantor Fitzgerald | $15 → $12 | Maintains | Overweight |
| 04/27/2023 | 719.67% | HC Wainwright & Co. | $25 → $10 | Maintains | Buy |
| 03/30/2023 | 1949.18% | HC Wainwright & Co. | → $25 | Reiterates | → Buy |
| 02/16/2023 | 1949.18% | HC Wainwright & Co. | → $25 | Reiterates | → Buy |
| 02/10/2023 | 801.64% | JonesTrading | → $11 | Initiates Coverage On | → Buy |
| 10/25/2022 | 1129.51% | Cantor Fitzgerald | → $15 | Initiates Coverage On | → Overweight |
| 06/21/2022 | 1949.18% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/20/2023 | 309.84% | HC Wainwright & Co. | 9 美元 → 5 美元 | 維護 | 買 |
| 09/26/2023 | 637.7% | 坎託·菲茨傑拉德 | → 9 美元 | 重申 | 超重 → 超重 |
| 09/22/2023 | 637.7% | HC Wainwright & Co. | 7 美元 → 9 美元 | 維護 | 買 |
| 09/14/2023 | 637.7% | 坎託·菲茨傑拉德 | → 9 美元 | 重申 | 超重 → 超重 |
| 08/22/2023 | 637.7% | 坎託·菲茨傑拉德 | → 9 美元 | 重申 | 超重 → 超重 |
| 08/18/2023 | 473.77% | HC Wainwright & Co. | 10 美元 → 7 美元 | 重申 | 購買 → 購買 |
| 06/01/2023 | 719.67% | HC Wainwright & Co. | → 10 美元 | 重申 | → 購買 |
| 05/18/2023 | 883.61% | 坎託·菲茨傑拉德 | 15 美元 → 12 美元 | 維護 | 超重 |
| 04/27/2023 | 719.67% | HC Wainwright & Co. | 25 美元 → 10 美元 | 維護 | 買 |
| 03/30/2023 | 1949.18% | HC Wainwright & Co. | → 25 美元 | 重申 | → 購買 |
| 02/16/2023 | 1949.18% | HC Wainwright & Co. | → 25 美元 | 重申 | → 購買 |
| 02/10/2023 | 801.64% | JonesTrading | → 11 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 10/25/2022 | 1129.51% | 坎託·菲茨傑拉德 | → 15 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 2022 年 6 月 21 日 | 1949.18% | HC Wainwright & Co. | → 25 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Mainz Biomed (MYNZ)?
Mainz Biomed（MYNZ）的目標價格是多少？
The latest price target for Mainz Biomed (NASDAQ: MYNZ) was reported by HC Wainwright & Co. on November 20, 2023. The analyst firm set a price target for $5.00 expecting MYNZ to rise to within 12 months (a possible 309.84% upside). 12 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月20日公佈了美因茨生物醫學（納斯達克股票代碼：MYNZ）的最新目標股價。該分析公司將目標股價定爲5.00美元，預計MYNZ將在12個月內升至12個月內（可能上漲309.84％）。去年有12家分析公司公佈了評級。
What is the most recent analyst rating for Mainz Biomed (MYNZ)?
美因茨生物醫學（MYNZ）的最新分析師評級是多少？
The latest analyst rating for Mainz Biomed (NASDAQ: MYNZ) was provided by HC Wainwright & Co., and Mainz Biomed maintained their buy rating.
美因茨生物醫學（納斯達克股票代碼：MYNZ）的最新分析師評級由HC Wainwright & Co. 提供，美因茨生物醫學維持買入評級。
When is the next analyst rating going to be posted or updated for Mainz Biomed (MYNZ)?
美因茨生物醫學（MYNZ）的下一次分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mainz Biomed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mainz Biomed was filed on November 20, 2023 so you should expect the next rating to be made available sometime around November 20, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與美因茨生物醫學的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。美因茨生物醫學的最新評級是在2023年11月20日公佈的，因此您應該預計下一個評級將在2024年11月20日左右公佈。
Is the Analyst Rating Mainz Biomed (MYNZ) correct?
分析師對美因茨生物醫學（MYNZ）的評級是否正確？
While ratings are subjective and will change, the latest Mainz Biomed (MYNZ) rating was a maintained with a price target of $9.00 to $5.00. The current price Mainz Biomed (MYNZ) is trading at is $1.22, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的美因茨生物醫學（MYNZ）評級維持不變，目標股價爲9.00美元至5.00美元。美因茨生物醫藥（MYNZ）目前的交易價格爲1.22美元，超出了分析師的預期區間。